PTC Therapeutics officer proposes $105K share sale
The 1,638 shares are listed as acquired from PTC Therapeutics, Inc. through a stock option exercise, with cash shown as payment.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
PTC Therapeutics, Inc. officer Mark Boulding reported a proposed sale of 1,638 common shares on October 5, 2026, with an aggregate market value of $104,883.45. He also reported sales of 5,079 common shares for $432,115.62 on July 6, 2026, and 2,813 common shares for $204,123.09 on August 17, 2026.
Key Figures
Key Terms
Rule 144 regulatory
Stock Option Exercise financial
attorney-in-fact regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.